沙库巴曲缬沙坦治疗糖尿病合并心血管并发症的研究进展  

Research Progress in the Treatment of Diabetes Mellitus with Cardiovascular Complications with Sacubitril Valsartan

作　　者：陈琳[1] 念馨[1] 蔡红雁[2] CHEN Lin;NIAN Xin;CAI Hongyan(Dept.of Endocrinology,The 1st Affiliated Hospital of Kunming Medical University,Kunming Yunnan 650032,China;Dept 2.of Cardiology,The 1st Affiliated Hospital of Kunming Medical University,Kunming Yunnan 650032,China)

机构地区：[1]昆明医科大学第一附属医院内分泌一科,云南昆明650032 [2]昆明医科大学第一附属医院心脏内二科,云南昆明650032

出　　处：《昆明医科大学学报》2024年第11期155-160,共6页Journal of Kunming Medical University

基　　金：国家自然科学基金资助项目(82270372);云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目(202201AY070001-066);云南省“兴滇英才支持计划”名医专项基金资助项目(RLMY20220005);云南省重大疑难疾病中西医临床协作试点基金资助项目(300073);昆明医科大学科技创新团队基金资助项目(CXTD202209)。

摘　　要：糖尿病由于多种因素常并发心血管并发症,心血管并发症也是糖尿病患者死亡的常见因素,因此,在改善糖尿病患者糖代谢同时也需控制心血管并发症。沙库巴曲缬沙坦是一种新型复合物,有着抑制脑啡肽酶和血管紧张素受体的双重作用,目前在临床上常作为心力衰竭患者的常用药物。近期的研究提示,沙库巴曲缬沙坦可能还存在着潜在的代谢益处,在改善糖尿病患者心功能的同时能改善血糖控制,有望成为糖尿病可常规使用的药物,带来心血管及代谢方面的益处。综述沙库巴曲缬沙坦在治疗糖尿病患者合并心血管疾病时的临床疗效及代谢益处。Diabetes often coexists with cardiovascular complications,which are also a common cause of death in diabetes patients.Therefore,in addition to improving glucose metabolism,it is also necessary to control cardiovascular complications in diabetes patients.Sacubitril valsartan is a novel compound with dual actions of inhibiting neprilysin and angiotensin receptor,and it is commonly used as a heart failure drug in clinical practice.Recent studies suggest that sacubitril valsartan may also have potential metabolic benefits,improving cardiac function while improving glycemic control in diabetes patients,and it is expected to become a drug that can be used routinely in diabetes,bringing cardiovascular and metabolic benefits.This review focuses on the clinical efficacy and metabolic benefits of sacubitril valsartan in the treatment of diabetes patients with cardiovascular diseases.

关 键 词：沙库巴曲缬沙坦 脑啡肽酶 肾素血管紧张素系统 利钠肽 血糖 

分 类 号：R587.1[医药卫生—内分泌]